1. Home/
  2. Compounds/
  3. tanespimycin:bortezomib (250:1 mol/mol)

tanespimycin:bortezomib (250:1 mol/mol)


SourcesNames Used
CTRPv2tanespimycin:bortezomib (250:1 mol/mol)
PharmacoGx tanespimycin:bortezomib (250:1 mol/mol)

Cell lines tested with tanespimycin:bortezomib (250:1 mol/mol)

797 cell lines have been tested with this compound, using data from 1 dataset(s).
2004 N/A CTRPv21
22RV1 prostate CTRPv21
23132-87 stomach CTRPv21
253J urinary tract CTRPv21
253J-BV urinary tract CTRPv21
42-MG-BA central nervous system CTRPv21
5637 urinary tract CTRPv21
639-V urinary tract CTRPv21
647-V urinary tract CTRPv21
697 haematopoietic and lymphoid tissue CTRPv21
Download CSV

Tissues tested with tanespimycin:bortezomib (250:1 mol/mol)

25 tissues have been tested with this compound, using data from 1 dataset(s).
central nervous systemCTRPv245
urinary tractCTRPv222
biliary tractCTRPv25
haematopoietic and lymphoid tissueCTRPv2135
autonomic gangliaCTRPv211
Download CSV
Download Data as CSV

Top molecular features associated with response to tanespimycin:bortezomib (250:1 mol/mol)

Feature TypeStandardized
Nominal ANOVA
mRNA NUP54 CTRPv2 AAC 0.2 6e-08
mRNA INTS7 CTRPv2 AAC 0.21 8e-08
mRNA LIN9 CTRPv2 AAC 0.2 1e-07
mRNA GTF3C6 CTRPv2 AAC 0.2 1e-07
mRNA GNPNAT1 CTRPv2 AAC 0.21 2e-07
mRNA LRP8 CTRPv2 AAC 0.19 4e-07
mRNA AC110615.1 CTRPv2 AAC 0.19 7e-07
mRNA PUS1 CTRPv2 AAC 0.18 1e-06
mRNA UCK2 CTRPv2 AAC 0.18 3e-06
mRNA WWC1 CTRPv2 AAC -0.21 4e-06
Download CSV